MILFORD, Pa., June 8, 2015 /PRNewswire/ -- Manzo
Pharmaceuticals, Inc. (OTCPink: MNZO), today announced Manzo
Pharmaceuticals has finished the development of its newest product,
a natural sleep aid that the company has named Somnaid™. This news
comes at the same time that Manzo Pharmaceuticals acknowledges
positive results on its preliminary human study, and is now
preparing to begin its full-scale human study of the company's
ground breaking lactose intolerance product, Lacto-Freedom™.
Somnaid™ will target a much larger demographic than the
company's previously released natural supplement product for babies
with colic, and offer consumers a natural sleep aid that is triple
acting, and designed specifically to deliver the right amounts of
its natural ingredients to the consumer. Somnaid™ has been in the
works for quite some time and the company CEO, Mr. Kenneth Manzo feels confident that it is better
than any other natural sleep aid on the market. "I drew upon my
extensive knowledge and many years of experience as a licensed
pharmacist to achieve the perfect formula for deep restful sleep,"
said Manzo. "I also wanted to focus on products that have a large
target market like Lacto-Freedom does in order to create a line of
products that is as profitable as it is effective." For more
information visit www.somnaid.com
The other important development for Manzo Pharmaceuticals is the
positive result from the preliminary study that was done recently
using Lacto-Freedom™ on a small group of human subjects. After the
success of the preliminary study, it has been decided that
Celprogen will be conducting the full-scale human study, in place
of the clinical research company previously chosen, which will
allow Manzo pharmaceuticals to get the product on the fast track to
public release. "We need to get Lacto-Freedom™ to the consumer as
quickly as possible. Every test we have done has had nothing but
tremendous results. We have tested, and tested, and tested again,
so after the full scale controlled human study, Lacto-Freedom™ will
be just about ready for public release, hopefully changing the
lives of millions of people all over the world," added Manzo.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company
engaged in the research, development, and testing of patented and
non-patented solutions and remedies. Most notably is a patented
solution for lactose intolerance, a natural remedy for colic in
babies, and a natural sleep aid. For more information follow
the company on twitter at @manzopharma, and visit
www.manzopharma.com.
DISCLAIMER:
This Press Release may contain certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. The Company has tried, whenever possible, to identify
these forward-looking statements using words such as "anticipates,"
"believes," "estimates," "expects," "plans," "intends," "potential"
and similar expressions. These statements reflect the Company's
current beliefs and are based upon information currently available
to it. Accordingly, such forward-looking statements involve known
and unknown risks, uncertainties and other factors which could
cause the Company's actual results, performance or achievements to
differ materially from those expressed in or implied by such
statements. The Company undertakes no obligation to update or
advise in the event of any change, addition or alteration to the
information catered in this Press Release including such
forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/manzo-pharmaceuticals-announces-exciting-new-product-release-as-the-company-prepares-for-the-full-scale-human-study-of-its-lacto-freedom-product-to-begin-300095221.html
SOURCE Manzo Pharmaceuticals, Inc.
